Glucagon-like peptide-1 receptor agonists are compounds that stimulate the activity of GLUCAGON-LIKE PEPTIDE-1 RECEPTOR . They were initially developed to treat type 2 diabetes and are highly effective for glycaemic control .

Retatrutide

Early-phase and translational research on retatrutide, a GLP-1/GIP/glucagon tri-agonist in development for obesity and metabolic disease.

Also called Retatrutide, LY3437943, triple incretin agonist

Sources: 12 new papers · 5 key papers · updated Oct 20, 2026

Overview

Unverified · drafted by AI from the sources cited below

Definition

Glucagon-like peptide-1 receptor agonists are compounds that stimulate the activity of GLUCAGON-LIKE PEPTIDE-1 RECEPTOR.1 They were initially developed to treat type 2 diabetes and are highly effective for glycaemic control.2

New research on Retatrutide

Pharmacy students’ knowledge and attitudes regarding GLP-1 receptor agonist adverse effects in obesity management: a cross-sectional study

Libyan Journal of Medicine — Khojah A — Oct 2026

Read paper

GLP-1 receptor agonist initiation and risk of psychiatric hospitalisation and emergency department presentation in adults with schizophrenia and type 2 diabetes in the USA: an observational cohort study using electronic health records data

The Lancet Psychiatry — Davoodian N — Oct 2026

Read paper

Incretin Mimetics and Alcohol‐Related Outcomes: A Structured Narrative Review

Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy — Goodyear C — Oct 2026

Read paper

The effects of improved access to diabetes medications on risk of Alzheimer's disease and related dementias

Alzheimer s & Dementia — Barthold D — Oct 2026

Read paper

Global Landscape and Thematic Evolution of Selective GLP ‐1 Receptor Agonists and GLP ‐1–Based Multi‐Receptor Agonists in Type 2 Diabetes Mellitus: A Bibliometric Analysis

Endocrinology Diabetes & Metabolism — Wang Y — Sep 2026

Read paper

Gastrointestinal adverse effects of GLP‐1 receptor agonists and dual GIP/GLP‐1 receptor agonists: A narrative expert review of approved therapies, oral formulations, and pipeline agents

Nutrition in Clinical Practice — Vikash F — Sep 2026

Read paper

Real-world treatment patterns and cost per patient achieving treatment targets among tirzepatide and semaglutide initiators in US patients with type 2 diabetes

Journal of Managed Care & Specialty Pharmacy — Hoog M — Sep 2026

Read paper

Study on the Regulatory Mechanism of GLP-1 Receptor Agonist Liraglutide in Diabetic Corneal Epithelial Wound Healing

Investigative Ophthalmology & Visual Science — Liu X — Sep 2026

Read paper

Return on investment of SGLT2 inhibitors and GLP-1 receptor agonists: Implications of real-world use for managed care

Journal of Managed Care & Specialty Pharmacy — Rapp H — Sep 2026

Read paper

GLP‐1R agonist semaglutide protects human forebrain organoids from cholesterol‐induced neurotoxicity

Alzheimer s & Dementia — Yu F — Sep 2026

Read paper

GLP-1 Receptor Agonist Coverage for Obesity in Medicaid and Total GLP-1 Receptor Agonist Utilization

JAMA Health Forum — Khanna R — Sep 2026

Read paper

Cardiovascular outcomes associated With GLP-1 and dual GLP-1/GIP receptor agonists in patients with type 2 diabetes and inflammatory bowel disease: A retrospective real-world cohort study

PLoS ONE — Kazi M — Sep 2026

Read paper

How this page is built

A clinical question appears here only when its condition matches this topic, an outcome and a comparator were extracted from the studies, at least two studies and a patient count are on file, and the certainty is low or higher.

Supports benefit, no benefit shown, and mixed describe the direction of the measured effect. No benefit shown means the evidence does not support a benefit. It is not a finding of harm. Too little evidence means the question did not clear that bar.

Study count, RCT count, and patient count are separate. The patient total adds only studies that are linked into a study family and whose sample size is not flagged as implausible. A reversal is listed only when at least one randomized trial sits on each side of the change.

The overview is drafted from the guideline recommendations, trials, papers, and questions on this page, and every sentence has to cite one of them. It stays unverified until an NPI-verified clinician or a Synapse admin approves it. Approving records that person's name.

Retatrutide

Overview

Definition

New research on Retatrutide

Key papers

How this page is built

Leading authors